In Silico Modeling of Nonspecific Binding to Human Liver Microsomes

Estimation of unbound fraction of substrate in microsomal incubation media is important in accurately predicting hepatic intrinsic clearance and drug-drug interactions. In this study, the unbound fraction of 1223 drug-like molecules in human liver microsomal incubation media has been determined using equilibrium dialysis. These compounds, which include 27 marketed drug molecules, cover a much broader range of physiochemical properties such as hydrophobicity, molecular weight, ionization state, and degree of binding than those examined in previous work. In developing the in silico model, we have used two-dimensional molecular descriptors including cLogP, Kier connectivity, shape, and E-state indices, a subset of MOE descriptors, and a set of absorption, disposition, metabolism, and excretion structural keys used for our in-house absorption, disposition, metabolism, excretion, and toxicity modeling. Hydrophobicity is the most important molecular property contributing to the nonspecific binding of substrate to microsomes. The prediction accuracy of the model is validated using a subset of 100 compounds, and 92% of the variance is accounted for by the model with a root mean square error (RMSE) of 0.10. For the training set of compounds, 99% of variance is accounted for by the model with a RMSE of 0.02. The performance of the developed model has been further tested using the 27 marketed drug molecules with a RMSE of 0.10 between the observed and the predicted unbound fraction values.

[1]  D. Greenblatt,et al.  Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[2]  L. Kier.  Indexes of molecular shape from chemical graphs , 1987, Medicinal research reviews.

[3]  L. Hall,et al.  Molecular Structure Description: The Electrotopological State , 1999 .

[4]  R. Venkataraghavan,et al.  Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..

[5]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[6]  J Brian Houston,et al.  BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT , 2006, Drug Metabolism and Disposition.

[7]  Kier Lb.  An index of flexibility from molecular shape descriptors. , 1989 .

[8]  Scott L Cockroft,et al.  The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[9]  Michael J Banker,et al.  Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. , 2003, Journal of pharmaceutical sciences.

[10]  Jing Lu,et al.  Development of in silico models for human liver microsomal stability , 2007, J. Comput. Aided Mol. Des..

[11]  T. Maurer,et al.  Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[12]  R. Obach.  The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[13]  Amy Roe,et al.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[14]  J B Houston,et al.  Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. , 2001, British journal of clinical pharmacology.

[15]  Shiew-Mei Huang,et al.  Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential—Toward a Consensus , 2001, Pharmaceutical Research.

[16]  R. Obach,et al.  Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[17]  R. Obach,et al.  Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[18]  Robert J Riley,et al.  THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES , 2005, Drug Metabolism and Disposition.

[19]  Robert P. Sheridan,et al.  Similarity to Molecules in the Training Set Is a Good Discriminator for Prediction Accuracy in QSAR , 2004, J. Chem. Inf. Model..

[20]  R J Riley,et al.  The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. , 2006, Current drug metabolism.

[21]  Paul Labute,et al.  Binary Quantitative Structure-Activity Relationship (QSAR) Analysis of Estrogen Receptor Ligands , 1999, J. Chem. Inf. Comput. Sci..

[22]  J. Wagner,et al.  Blood Levels of Drug at the Equilibrium State after Multiple Dosing , 1965, Nature.

[23]  T. Maurer,et al.  Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery , 2002, Biopharmaceutics & drug disposition.

[24]  Michael J. Sorich,et al.  Molecular Modeling Approaches for the Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes , 2006, J. Chem. Inf. Model..